|
Asian Journal of Andrology (2009) 11: 629-637. doi: 10.1038/aja.2009.48; published online 24 August 2009.
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study
Ferdinando Fusco1, Riccardo Sicuteri2, Andrea Rossi2, Stathis Kontodimas3, Jose Maria Haro4, Ciro Imbimbo1 and Vincenzo Mirone for the Italian EDOS Study Group*
1 Clinica Urologica – Università Federico II, Napoli 80100, Italy
2 Ely Lilly Italia, Firenze 50019, Italy
3 Eli Lilly and Company, Windlesham, Surrey GU20 6PH, UK
4 Fundació Sant Joan de Déu, Esplugues de Llobregat 08950, Spain
Correspondence: Dr Ferdinando Fusco, Urologic Clinic, University Federico II of Naples–Via S. Pansini, 5–80132 Naples, Italy. Fax: +39-081-545-2959 E-mail: ferdinando-fusco@libero.it
* Member of the Italian EDOS study group are listed in Appendix.
Received 5 July 2009; Revised 0000; Accepted 10 July 2009; Published online 24 August 2009.
| Abstract |
The Erectile Dysfunction Observational Study (EDOS) is a 6-months observational prospective multicentric study enrolling men with erectile dysfunction (ED) who asked, to be started on a treatment or to change a previous treatment. Aims of the study were to analyse the pattern of treatment and compare the efficacy of treatments used. Patients were enrolled during a normal hospital visit and were prescribed a treatment for ED. They were asked at baseline and after 3 and 6 months, to answer a set of questions from the International Index of Erectile Function, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and Short Form of the Psychological and Interpersonal Relationships Scale questionnaires (SF-PAIRS). Clinicians were free to prescribe any therapy for ED available in the market, and to change therapy at any time during the study. Out of 1 338 patients, available for analysis at 6 months, 624 (47%) changed their treatment during the study and 714 (53%) continued with the drug prescribed at baseline. Patients assuming tadalafil had a significantly higher probability of maintaining the same treatment compared to sildenafil or vardenafil. There was no clinically significant difference in terms of efficacy, patient satisfaction, self-confidence and spontaneity between the different inhibitors of PDE5. The 'time concerns' domain score of SF-PAIRS, was statistically better in patients assuming tadalafil. In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.
Keywords: clinical practice, Italy, phosphodiesterase type 5 inhibitors, sildenafil, tadalafil, vardenafil |
|
